These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 21340661)

  • 21. Excretion of the dipeptidyl peptidase-4 inhibitor linagliptin in rats is primarily by biliary excretion and P-gp-mediated efflux.
    Fuchs H; Runge F; Held HD
    Eur J Pharm Sci; 2012 Apr; 45(5):533-8. PubMed ID: 22198311
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers.
    Macha S; Sennewald R; Rose P; Schoene K; Pinnetti S; Woerle HJ; Broedl UC
    Clin Ther; 2013 Mar; 35(3):226-35. PubMed ID: 23497760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of food and tablet-dissolution characteristics on the bioavailability of linagliptin fixed-dose combination with metformin: evidence from two randomized trials.
    Metzmann K; Schnell D; Jungnik A; Ring A; Theodor R; Hohl K; Meinicke T; Friedrich C
    Int J Clin Pharmacol Ther; 2014 Jul; 52(7):549-63. PubMed ID: 24755124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*).
    Graefe-Mody U; Friedrich C; Port A; Ring A; Retlich S; Heise T; Halabi A; Woerle HJ
    Diabetes Obes Metab; 2011 Oct; 13(10):939-46. PubMed ID: 21672124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized, open-label, crossover study evaluating the effect of food on the relative bioavailability of linagliptin in healthy subjects.
    Graefe-Mody U; Giessmann T; Ring A; Iovino M; Woerle HJ
    Clin Ther; 2011 Aug; 33(8):1096-103. PubMed ID: 21803422
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers.
    He YL; Sabo R; Sunkara G; Bizot MN; Riviere GJ; Leon S; Ligueros-Saylan M; Dole WP; Howard D
    J Clin Pharmacol; 2007 Aug; 47(8):998-1004. PubMed ID: 17660482
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Linagliptin fixed-dose combination with metformin is bioequivalent to co-administration of linagliptin and metformin as individual tablets.
    Buschke S; Ring A; Friedrich C; Metzmann K; Meinicke T
    Int J Clin Pharmacol Ther; 2014 Jul; 52(7):537-48. PubMed ID: 24755123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356)--investigations in DPP-4 deficient and wildtype rats.
    Retlich S; Withopf B; Greischel A; Staab A; Jaehde U; Fuchs H
    Biopharm Drug Dispos; 2009 Nov; 30(8):422-36. PubMed ID: 19771584
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Linagliptin: in type 2 diabetes mellitus.
    Scott LJ
    Drugs; 2011 Mar; 71(5):611-24. PubMed ID: 21443284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The dipeptidyl peptidase-4 inhibitor linagliptin exhibits time- and dose-dependent localization in kidney, liver, and intestine after intravenous dosing: results from high resolution autoradiography in rats.
    Greischel A; Binder R; Baierl J
    Drug Metab Dispos; 2010 Sep; 38(9):1443-8. PubMed ID: 20538719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes.
    Forst T; Pfützner A
    Expert Opin Pharmacother; 2012 Jan; 13(1):101-10. PubMed ID: 22149370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of tegaserod (HTF 919) on the pharmacokinetics and pharmacodynamics of digoxin in healthy subjects.
    Zhou H; Horowitz A; Ledford PC; Hubert M; Appel-Dingemanse S; Osborne S; McLeod JF
    J Clin Pharmacol; 2001 Oct; 41(10):1131-9. PubMed ID: 11583482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of telmisartan on the steady-state pharmacokinetics of digoxin in healthy male volunteers.
    Stangier J; Su CA; Hendriks MG; van Lier JJ; Sollie FA; Oosterhuis B; Jonkman JH
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 1):1373-9. PubMed ID: 11185636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of digoxin in healthy subjects receiving taranabant, a novel cannabinoid-1 receptor inverse agonist.
    Denker AE; Morelli G; Vessey LK; Li S; Yuan J; Dunbar S; Lewis NM; Taggart W; Wagner JA
    Adv Ther; 2009 Feb; 26(2):230-40. PubMed ID: 19219408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers.
    De Smet M; Schoors DF; De Meyer G; Verbesselt R; Goldberg MR; Fitzpatrick V; Somers G
    Br J Clin Pharmacol; 1995 Dec; 40(6):571-5. PubMed ID: 8703664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Absence of an effect of a single-dose deferasirox on the steady-state pharmacokinetics of digoxin.
    Sechaud R; Robeva A; Belleli R; Balez S
    Int J Clin Pharmacol Ther; 2008 Oct; 46(10):519-26. PubMed ID: 18826866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes.
    Lingvay I; Beetz N; Sennewald R; Schuler-Metz A; Bertulis J; Loley C; Lang B; Lippert C; Lee J; Manning LS; Terada D
    Postgrad Med; 2020 May; 132(4):337-345. PubMed ID: 32366156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Linagliptin: a novel methylxanthin based approved dipeptidyl peptidase-4 inhibitor.
    Agrawal R; Jain P; Dikshit SN
    Curr Drug Targets; 2012 Jun; 13(7):970-83. PubMed ID: 22420306
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of pharmacokinetic interaction between gemifloxacin and digoxin in healthy elderly volunteers.
    Vousden M; Allen A; Lewis A; Ehren N
    Chemotherapy; 1999; 45(6):485-90. PubMed ID: 10567779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.